Ocular Therapeutix (OCUL) Total Current Liabilities (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Total Current Liabilities of $49.2 million for Q2 2026, up 14.54% year-over-year from $42.9 million in Q2 2025, and up 3.13% on a QoQ basis from $47.7 million in Q1 2026.
Ocular Therapeutix (OCUL) Total Current Liabilities (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Total Current Liabilities for 14 years, with the latest figure at $49.2 million in Q2 2026.
- Total Current Liabilities for Q2 2026 came in at $49.2 million, up 14.54% year-over-year; the trailing twelve-month figure through Jun 2026 was $49.2 million (up 14.54% YoY), and the FY2025 annual result was $50.8 million, up 22.86% from the prior year.
- Total Current Liabilities rose to $49.2 million in Q2 2026, from $47.7 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $50.8 million in Q4 2025 and troughed at $24.0 million in Q1 2022.
- A 5-year average of $36.3 million and a median of $35.0 million in 2023 frame the typical range for Total Current Liabilities.
- The widest annual swing landed in 2024, when Total Current Liabilities slipped 18.23%; it then soared 56.09% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $31.4 million in 2022, then advanced by 11.15% to $34.9 million in 2023, then rose by 18.51% to $41.4 million in 2024, then climbed by 22.86% to $50.8 million in 2025, then slipped by 3.21% to $49.2 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $49.2 million in Q2 2026, $47.7 million in Q1 2026, and $50.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 49.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.17 Mn |
| Mar 31, 2026 | 47.68 Mn |
| Dec 31, 2025 | 50.81 Mn |
| Sep 30, 2025 | 49.29 Mn |
| Jun 30, 2025 | 42.93 Mn |
| Mar 31, 2025 | 37.93 Mn |
| Dec 31, 2024 | 41.35 Mn |
| Sep 30, 2024 | 36.36 Mn |
| Jun 30, 2024 | 29.97 Mn |
| Mar 31, 2024 | 24.30 Mn |
| Dec 31, 2023 | 34.90 Mn |
| Sep 30, 2023 | 35.07 Mn |
| Jun 30, 2023 | 32.36 Mn |
| Mar 31, 2023 | 29.72 Mn |
| Dec 31, 2022 | 31.40 Mn |
| Sep 30, 2022 | 29.27 Mn |
| Jun 30, 2022 | 26.11 Mn |
| Mar 31, 2022 | 23.96 Mn |
| Dec 31, 2021 | 26.34 Mn |
| Sep 30, 2021 | 25.16 Mn |